We aimed to identify the prevalence of circadian phase and phase angle abnormalities in patients with insomnia. Methods: We conducted a cross-sectional, multicenter study at three sleep laboratories in the United States and Australia. Patients with insomnia and healthy control participants completed a sleep log for 7 days. Circadian phase was assessed from salivary dim light melatonin onset (DLMO) time during a 12-hour laboratory visit. Results: Seventy-nine patients meeting the Research Diagnostic Criteria for Primary, Psychophysiological, Paradoxical, and/or Idiopathic Childhood Insomnia (46 females, 35.5 ± 12.3 years [M ± SD]) and 21 controls (14 females, 34.4 ± 11.8 years). As compared to controls, patients with insomnia tried to initiate sleep on average at the same clock time (24:17 ± 1:17 hours vs. 24:13 ± 1:30 hours, respectively; p = .84) but had a later average DLMO times (20:56 ± 1:55 hours, 18:17-01:21 vs. 22:02 ± 2:02 hours, 17:11-04:52, respectively; p = .04). Consequently, patients with insomnia slept at an earlier circadian phase than controls (phase angle, bedtime-DLMO 2:13 hours (± 1:43) vs. 3:10 hours (± 1:08), respectively; p = .008), of whom 10% tried to sleep at or before DLMO (compared to 0 controls), and 22% tried to sleep before or within 1 hour after DLMO (compared to 6% of controls). Conclusions: A substantial proportion (10%-22%) of patients with insomnia initiate sleep at too early a circadian phase, implicating a circadian etiology for their insomnia. Outpatient circadian phase assessments should be considered to improve differential diagnoses in insomnia and to inform the development of appropriately timed circadian-based treatments.
INTRODUCTION
Insomnia is a highly prevalent sleep disorder, affecting 10%-13% of the population chronically, with up to 35% experiencing some degree of insomnia symptoms. [1] [2] [3] In addition to the consequences for patient health and well being, loss of work time and efficiency due to insomnia is estimated to cost tens of billions of dollars annually in the United States alone. 4 Identifying the underlying causes of insomnia is vital for its correct diagnosis and treatment.
The duration and quality of sleep are dependent on the time when it occurs-it is generally easier to go to sleep for 8 hours at 11:00 pm than it is at 11:00 am-and more specifically depending on the timing of sleep relative to the endogenous circadian cycle. [5] [6] [7] The circadian sleep propensity rhythm, along with many other physiological and behavioral rhythms such as alertness and performance patterns are controlled by the endogenous 24-hour pacemaker located in the suprachiasmatic nuclei of the hypothalamus. This pacemaker generates near-24-hour rhythms which are synchronized to 24 hours by daily exposure to the 24-hour light-dark cycle. 8 Even small changes in the circadian phase at which sleep occurs can have dramatic effects on the quality and duration of sleep. 9 There is only a relatively small target "window" of time for optimal sleep initiation and maintenance throughout the night. The circadian system works in cooperation with another oscillator, the sleep homeostat, which increases sleep propensity with increasing hours awake. Homeostatic sleep pressure is lowest shortly after waking and highest just before sleep. The circadian propensity for sleepiness is highest just before habitual wake time, at ~03:00-06:00 am and is lowest just before habitual sleep time, ~07:00-10:00 pm. 7, 10 The latter time is often called the "wake maintenance zone" (WMZ), during which it is difficult to fall asleep. The WMZ ends with the onset of melatonin production. 10, 11 Sleep consolidation occurs when sleep is appropriately timed relative to the homeostatic and circadian drives. Circadian misalignment, that is, failing to hit this target and attempting sleep too early in the circadian cycle, during the WMZ, can result in difficulty falling asleep, whereas attempting to sleep too late in the cycle can cause difficulty maintaining sleep or early awakening. 7, 12 Disorders in the circadian phase at which sleep occurs or is attempted, or "phase angle" disorders, underlie sleep disturbances associated with adolescence, diurnal preference and aging, 13 and predict the time course of alertness and performance patterns through the day. 14 The inability to sleep at the correct time is also influenced by social and environmental factors, such as work and school schedules, family commitments, caffeine and other stimulant use, inappropriate light exposure etc., exacerbating inappropriate timing of sleep.
Extreme examples of such sleep phase disorders are seen in Advanced Sleep Wake Phase Disorder (ASWPD) and Delayed
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Sleep Wake Phase Disorder (DSWPD) where sleep occurs either too early or too late in the social day, respectively. Even within the normal population, however, there is a 4-to 5-hour range in the timing of endogenous circadian rhythms relative to sleep, [15] [16] [17] [18] which at the extremes would be the equivalent of two people sleeping at the same actual time in London and New York, 19 and therefore the phase at which sleep occurs has a major impact on a much larger proportion of the population. Previous studies of smaller cohorts (n < 25) of patients with insomnia who had complaints of early morning awakening insomnia have shown that the circadian phase of temperature and dim light melatonin onset (DLMO), assessed under laboratory constant routine conditions, is shifted earlier in time relative to the normal range. 20, 21 In the current study, we conducted a combined home and laboratory outpatient assessment to evaluate the prevalence of circadian phase disorders in insomnia using melatonin as a circadian phase marker. We hypothesized that patients with chronic insomnia would show a higher prevalence and greater range of abnormal circadian phases and consequently be more likely to sleep at an inappropriate circadian phase than control participants.
METHODS

Participants
A total of 101 participants were recruited from the general community to one of three study sites: Boston, United States (n = 75); Melbourne, Australia (n = 20); or Philadelphia, United States (n = 6). The study was approved by the Partners Human Research Committee, the Alfred Human Research Ethics Committee, and the University of Pennsylvania Institutional Review Board. All participants provided written informed consent.
The study methods have been described elsewhere; 22 in brief, participants were required to be aged 18 to 65 years, have a body mass index between 18 and 30 kg/m 2 , and not to have smoked more than five cigarettes per week or used other tobacco products more than once per week in the previous 3 months. Participants were required to report habitual caffeine consumption less than 300 mg per day on average and moderate alcohol intake (for men: an average of no more than four standard drinks per day, no more than 28 standard drinks per week, and no more than six standard drinks in any 1 day in the past month; for women, an average of no more than two standard drinks per day, no more than 14 standard drinks per week, and no more than four standard drinks in any 1 day in the past month). Participants were excluded if they reported night shift work in the past 2 years (at least 6 hours of work between 10:00 pm and 08:00 am), transmeridian travel (≥ two time zones) in the past 2 months, and/or a habitual sleep onset time earlier than 09:00 pm or later than 03:00 am. Pregnancy or lactation as well as perimenopausal or menopausal symptoms were also exclusion criteria.
Health was assessed by medical history, physical examination, electrocardiography, blood biochemistry, hematology, urinalysis, and urine toxicology. Participants were included if no clinically significant deviations from normal were present. Participants were also required to have no history of drug or alcohol abuse in the past 12 months, no current use of any drugs or medications likely to affect sleep, alertness, circadian rhythms, or melatonin (including beta-blockers, nonsteroidal anti-inflammatory drugs), or if appropriate, were willing to discontinue the medication(s) for at least 2 weeks prior to enrolment and throughout the study with consent from their treating clinician. Participants were excluded if they reported the current use of medications for a psychiatric disorder or the presence of major depressive disorder or other severe psychopathological condition. Participants were assessed by a physician with specialist training in sleep medicine.
Sleep, physical health, and mental health were evaluated using the following self-report questionnaires, administered prior to the laboratory visit: Beck Depression Inventory II, 23 State-Trait Anxiety Inventory-Trait version, 24 Pittsburgh Sleep Quality Index, 25 Fatigue Severity Scale, 26 Athens Insomnia Scale, 27 Sleep Hygiene Questionnaire, 28 Dysfunctional Beliefs and Attitudes About Sleep, 29 Epworth Sleepiness Scale, 30 Short Form Health Survey of Medical Outcomes (SF-36), 31 and the Berlin Questionnaire. 32 Participants also completed a series of cognitive tests during the laboratory visit, and these data were published previously along with some of the self-report questionnaire and sleep data.
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Insomnia Group
Insomnia participants were eligible for inclusion if they met the Research Diagnostic Criteria (RDC) for Insomnia Disorder according to the International Classification for Sleep Disorders 2 criteria, as well as the RDC for Primary Insomnia, Psychophysiological Insomnia, Paradoxical Insomnia, and/ or Idiopathic Childhood Insomnia. 33 Determination was made through clinical history and review of questionnaires by a certified sleep clinician. Where participants met diagnostic criteria for more than one insomnia disorder, both were recorded. Participants were not eligible if, based on the clinician's assessment, they met the RDC for Insomnia related to any of the following: Periodic Limb Movement Disorder, Sleep Apnea, Drug or Substance and/or Medical Condition. Insomnia participants were required to score from 10 to 28 inclusive on the Insomnia Severity Index. A positive sleep apnea screening result on the Berlin Questionnaire was exclusionary. Past diagnosis of a comorbid psychiatric disorder was also exclusionary, per the RDC for Insomnia Disorder.
Control Group
Participants in the control group were included if they met RDC for Normal Sleepers 33 reported habitual sleep duration of greater than 6.0 hours and less than 9.5 hours, and scored less than eight on the Insomnia Severity Index. Individuals in the control group were excluded if they reported a positive score on the Berlin Questionnaire. Control participants were matched to 20 of the first 21 patients with insomnia by gender and age in 5-year blocks.
Prelaboratory Protocol
Following screening and until study completion, participants were asked not to take any new prescription or nonprescription medications or supplements and refrain from using recreational drugs. This was verified by urine toxicology tests during the screening visit and on admission to the laboratory. Participants were instructed not to modify their caffeine, nicotine, or alcohol intake from the levels reported at screening except for 48 hours prior to their laboratory visit, when participants were instructed to abstain from caffeine and nicotine.
Participants maintained their usual sleep-wake pattern in their home environment for at least 7 days prior to the laboratory visit, verified by daily sleep/activity diaries, actigraphy and light exposure monitoring (Actiwatch-L, Minimitter, Bend, OR), and daily call-in to a time-stamped voicemail service at bedtime and at waketime. Sleep diary information was used to make all sleep calculations for comparison to circadian phase estimates. Based on the daily call-in times, each participant's habitual average bedtime across the seven days prior to the laboratory visit was calculated to determine the timing of the laboratory visit. Two days prior to the study visit, participants were asked to collect 48-hour sequential urine samples approximately 4-hourly samples during the day and 8-hourly overnight.
Laboratory Protocol
Participants attended a ~12-hour laboratory visit at the Intensive Physiologic Monitoring Unit, Brigham and Women's Hospital (BWH; Boston, MA), the Monash University Sleep Laboratory (Melbourne, Australia), or the Clinical and Translational Research Center Sleep Laboratory (University of Pennsylvania, Philadelphia, PA). Laboratory events were scheduled relative to each participant's mean habitual bedtime, and participants were admitted to the laboratory approximately 9 hours prior to their habitual bedtime. The study ended 3 hours following their habitual bedtime, and they were provided with a cab home following completion of study procedures.
During the laboratory visit, participants remained in a light-controlled, sound-attenuated, and temperature-controlled suite. Ambient light levels were maintained at <10 lux when measured at the level of the eye in the vertical plane. Saliva samples were collected hourly during the laboratory portion of the study. A modified constant posture protocol was imposed; participants were seated at least 20 minutes prior to each saliva sample, food intake was standardized for timing and content, and wakefulness was monitored by direct observation by research staff throughout the laboratory visit. Urine sample collection continued in 4-hour blocks while in the laboratory. Participants were free to engage in sedentary activities at times when they were not required to undertake study procedures.
Circadian Phase Analysis
Circadian phase was calculated from melatonin timing in both saliva and urine. Saliva was assessed as described in Voultsios et al. 34 The DLMO was calculated as the clock time when the melatonin level crossed a 3 pg/mL threshold and remained above that threshold for at least another sample.
The determination of phase angle normality was performed in two ways. There are no clinical standards to determine an abnormal phase angle between sleep timing and circadian phase. The normal range comparison for salivary DLMO was adapted from plasma DLMO times found in St Hilaire et al., 2013. Saliva levels are approximately a third of that in plasma, 34 and therefore, a 3pg/mL saliva value is considered equivalent to 10 pg/mL in plasma. 35 In the St Hilaire et al. study (melatonin collected under <3 lux of light starting 8 hours after waketime while maintaining a fixed sleep-wake/dark-light schedule), 36 no individuals (0/32) had a DLMO that occurred at or after sleep onset. We therefore determined the prevalence of insomnia and control patients who tried to initiate sleep before DLMO. Further observation of the frequency distribution also showed that individuals also rarely slept in the hour after DLMO (6%, 2/32). We therefore also determined the prevalence of insomnia and control patients who tried to initiate sleep within the hour after DLMO, at DLMO, or before DLMO.
Urine collection and 6-sulfatoxymelatonin (aMT6s) radioimmunoassay procedures were performed as described by Lockley et al. 37 aMT6s values in ng/mL were converted to ng/hour and subjected to best fit cosine analysis (SAS software, version 9.2, Cary, NC) to determine the aMT6s acrophase. Results were used in the present analysis at various levels of significance as described in the results (p < .05, p < .20). 38 The normal range comparison for aMT6s acrophase was adapted from Lockley et al.
37
Statistical Analysis Univariate summary measures were calculated for patients with insomnia and controls. Differences between groups were assessed using Welch's t-test for unequal sample sizes and unequal variances for continuous outcomes among the entire cohort. Differences between categorical outcomes were assessed using chi-square tests. Pearson correlations were used to compare the relationship between continuous variables. Differences between the matched sample groups were assessed using paired t-tests.
RESULTS
From an initial sample of 80 individuals with insomnia and 21 healthy control participants, one insomnia patient was excluded due to nonadherence with the protocol. Three patients with insomnia and one healthy control did not complete the laboratory component of the study, but they did complete the homebased sleep diaries and urine samples for the phase assessment. Data from these participants are included in the final sample of 79 patients with insomnia (46 female) aged 35.5 ± 12.3 years (mean ± SD) and 21 control participants (14 female) aged 34.8 ± 12.1 years. In some cases, a small subset of participants chose not to answer all of the questions necessary to compute composite scores on the background questionnaires or from the sleep diary. The number of participants contributing to each outcome is indicated in the respective tables.
The majority of patients with insomnia were diagnosed with primary and psychophysiological insomnia combined (n = 45, 57%), with 22% diagnosed with psychophysiological insomnia alone, and 15% diagnosed with primary insomnia (Table 1) . Patients with insomnia were similar to control participants in baseline demographic characteristics (Table 2) .
Sleep Assessment
As expected, patients differed from controls on several self-reported sleep outcomes during the 7 days prior to the study (Table 2) . Patients reported a similar bedtime (24:13 ± 1:30 hours) and wake time (7:44 ± 1:39 hours) compared to controls (bedtime, 24:17 ± 1:17 hours; wake time, 7:58 ± 1:21 hours; p = .84 and p = .52, respectively) but with a longer average sleep 
Circadian Phase Assessment
Three patients with insomnia and one control completed the home-based sleep diaries and urine samples for phase assessment but did not complete the laboratory visit. Therefore, saliva data from 86 participants (68 patients and 18 controls) are included. Furthermore, two control participants and one insomnia patient were not compliant with the urine sample collection protocol and therefore data from 97 participants were assessed using the home-based urine sample collection (Supplemental Information).
Salivary DLMO
The mean (± SD) salivary DLMO was significantly later for patients (22:02 ± 2:02 hh:mm) compared to controls (20:56 ± 1:55 hh:mm; p = .04; Table 2 , Figures 1 and 2) . In addition, patients with insomnia had a wider range of DLMO times (17:11-03:52 hh:mm, range 10:41 hours) compared to controls (18:17-01:22 hh:mm, range 7:04 hours; Figure 1 ).
The mean phase angle for salivary DLMO relative to bedtime was 2:13 hours (± 1:43) among patients and 3:10 hours (± 1:08) among controls, indicating that, on average, patients with insomnia were attempting to sleep significantly earlier in their circadian cycle (i.e., sooner after DLMO) than controls (p = .008; Figure 3 ). The prevalence of having a DLMO value at or after trying to sleep was 10% (n = 7) in the patients with insomnia, and zero in the control group (Table 3, Figure 1 ). This subset of patients with insomnia had later sleep onset and sleep offset times, a later DLMO time and a reduced phase angle compared to the other 61 patients with insomnia without a severe phase abnormality (Table 3) . We further classified the phase angle between DLMO and bedtime in patients using a 1-hour criterion (i.e., trying to sleep within an hour after DLMO, or at or before DLMO) and 22% of patients (15/68) and 6% of controls (1/18) exhibited a short phase angle when classified this way (Table 3, Figure 1 ).
We subdivided the insomnia cohort between those with sleep onset latencies (SOL) of >40 minutes and <40 minutes in order to determine the proportion of individuals captured by such a potential screening criterion. We found that 34 patients had SOL > 40 minutes. Of the seven patients who attempted to sleep before DLMO, five exhibited SOL > 40 minutes (71%; 15% of those with SOL > 40 minutes). Of the 15 patients who attempted to sleep within 1 hour of DLMO, 10 exhibited SOL > 40 minutes (67%; 30% of those with SOL > 40 minutes).
Phase Angle and Sleep Outcomes
There were differences in the relationship between bedtime phase angle (i.e., the timing of attempting to sleep relative to DLMO) and sleep outcomes between patients with insomnia overall and controls ( Figure 3 ). There was a significant negative association between phase angle and sleep latency among patients with insomnia (r 2 = 0.10; p = .007), that is, patients who attempted to sleep before DLMO, during the WMZ, experienced longer sleep latencies than those attempting to sleep at a later circadian phase. Consequently, patients with insomnia who went to bed at an early circadian phase spent more time in bed compared to those who went to bed later relative to DLMO (r 2 = 0.13; p = .003). Among controls, there was no relationship between phase angle and sleep latency (r 2 = 0.00001; p = .99) nor between time in bed and phase angle (r 2 = 0.03; p = .50) although there were no control participants who attempted sleep before DLMO. We did find, however, that the Morningness-Eveningness Questionnaire was associated with phase angle among controls (r 2 = 0.43; p = .01) but not among patients with insomnia (r 2 = 0.01; p = .47).
Paired Analysis
In the paired analysis, sleep outcomes were similar to the analysis in the entire cohort among patients with insomnia who reported longer sleep latency; more awakenings of a longer duration; and decreased sleep duration, sleep efficiency, and sleep quality compared to controls (Table 2 ). There were 18/20 paired salivary DLMO data sets available for analysis due to one insomnia patient and one control participant having indeterminate DLMO values (i.e., one participant had all melatonin values above the threshold and one participant had melatonin values that fluctuated above and below the threshold) and 12/20 urinary aMT6s data sets, due to seven participants having nonsignificant cosinor fits and missing data for one control participant who was not compliant with the protocol. Circadian phase was later for patients with insomnia compared to controls as measured by saliva and urine, but this result was not statistically different, which is likely due to the low sample size available for each measure.
DISCUSSION
We found evidence that inappropriate timing of sleep relative to circadian phase contributes to insomnia. At least 10% and likely more than 20% of patients with insomnia had an abnormal phase angle that was not diagnosed as such by a standard clinical examination. While patients with insomnia tried to initiate sleep at the same clock time as controls, their circadian clock was delayed by more than an hour on average, causing a mismatch in the timing of attempted sleep relative to the melatonin rhythm, an established marker of the timing of the circadian pacemaker. Ten percent of patients had an extreme abnormal phase angle, attempting sleep at the time of or before DLMO, and an additional 12% of patients tried to sleep within an hour after DLMO, totaling at least 22% with an abnormal phase angle according to these criteria. In attempting to sleep at an earlier circadian phase, patients with insomnia increase the likelihood that the sleep episode coincides with the WMZ, or "forbidden zone" for sleep, therefore prolonging sleep latency, as illustrated most clearly in those patients who attempted sleep before DLMO. In this sample, we observed a wider range in DLMO and aMT6s circadian phase markers among patients compared to controls, suggesting that there may be more variability in the phase of circadian entrainment and a higher risk of sleeping at an abnormal circadian phase in patients. Unlike control participants, sleep among patients with insomnia was not correlated with their diurnal preference, a finding that dampens the utility of such questionnaires for the diagnosis of circadian phase-related insomnia. Routine assessment of circadian phase is indicated to identify the subset of patients with a high risk of a circadian rhythm abnormalities, along with the development and testing of circadian-informed treatment paradigms to encourage sleep at a more appropriate circadian phase and to ensure that current therapies are not mistimed relative to circadian time, which might attenuate therapeutic benefits. 39 In our sample, patients reported sleeping just over 6 hours on average, while controls reported sleeping seven and a half hours. This finding suggests that patients with insomnia accumulate greater sleep debt each day than controls, yet this increased sleep pressure does not facilitate initiation of sleep, as patients maintain a long sleep latency, on average. Many patients with insomnia get into bed early due to feeling fatigued, without necessarily being sleepy, which may contribute to the long sleep latencies. It is also possible that the short sleep duration is due to the patients under-reporting their actual sleep duration. In most patients, these long latencies do not appear to have a circadian basis (unless circadian sleep-wake regulation is perturbed at a more fundamental level in insomnia, a hypothesis without evidence at this point), although those patients with insomnia who had the earliest phase angles (trying to sleep at or before DLMO) did exhibit the longest latencies, suggesting that the WMZ contributes at least to their symptomology. It is important to note that our sample was comprised of a cohort of patients with insomnia that was not selected on the basis of having an underlying circadian rhythm disorder identified as the cause of insomnia symptoms. Others have shown that patients with insomnia who have a primary complaint of early morning awakening have an earlier DLMO and 6-aMT6s peak relative to controls. 21 Similarly, patients with a primary complaint of sleep onset insomnia have been shown to have a delayed core body temperature nadir compared to healthy controls. 40 Wright et al. 41 evaluated the relationship between DLMO and fall asleep time and found that a large proportion of patients with sleep onset insomnia have a delayed DLMO (46/84). These findings are similar to those reported by Kerkhof and van Vianen who found that sleep onset insomnia was associated with a relative delay in circadian phase and that short sleep duration in insomnia was associated with an early circadian phase. 42 Although these findings are similar to the present report, our findings suggest that circadian phase contributes to a larger proportion of insomnia than has previously been identified in the population of individuals with typical insomnia complaints. This may relate to the fact that we used phase angle (i.e., the time between DLMO and bedtime) to classify whether or not an individual was likely to have a circadian phase issue contributing to their insomnia, while prior studies used the clock time of DLMO and bedtime.
In our sample, we found that the morningness-eveningness questionnaire was not associated with phase angle. This may be because many of the participants who attempted to sleep within 1 hour of DLMO or before had a late DLMO time (i.e., after midnight). It is possible that some individuals were attempting to maintain a socially normal bedtime that was mistimed relative to their circadian phase. It is also possible that some of the patients with insomnia are unable to estimate their endogenous sleep drive-a "circadian state misperception," as it were. Self-reported morningness-eveningness preference is correlated with circadian phase in patients with ASWPD and DSWPD, where patients' sleep timing is typically very early or very late, making it easier to recognize in clinical practice. 43, 44 Our observation that the cohort of patients with modest circadian misalignment do not appear to shift their sleep timing in a consistent manner relative to their DLMO time suggests that such modest circadian phase abnormalities in insomnia may be more difficult for a clinician to detect. This combination of factors makes it likely that modest circadian abnormalities are widely underestimated in clinical practice. Consequently, objective measurements of circadian phase, rather than questionnaire-based assessments, are required to detect the contribution of circadian phase to insomnia symptoms.
Given our findings, it is likely that clinical interventions to correct the timing of sleep relative to circadian phase should be considered in conjunction with traditional insomnia therapy, particularly for individuals who present with long sleep latencies. Given that the direction and magnitude of circadian phase resetting, as described by the Phase Response Curve, depends on the internal circadian time of administration, such information is vital in order to time the treatment correctly. 39 Failure to do so may result in ineffective treatment or even treatment that exacerbates the insomnia by shifting the pacemaker in the opposite direction to that required. Knowledge of circadian phase may also be important when scheduling sleep restriction, which will alter light-dark exposure timing and may inadvertently change phase and cause a phase shift in the wrong direction. Prior studies have demonstrated that appropriately-timed bright light in the evening is capable of shifting circadian phase later, leading to an improvement in symptoms among patients with insomnia that have circadian-induced early morning waking insomnia. 20, 45 Our study is not without limitations. We recruited patients with insomnia from the general population in order to assess circadian phase in this patient group and selected only a subset of all insomnia disorder subtypes, and those without psychiatric disorders or current hypnotic treatments. A subset of these patients showed circadian misalignment. Future studies should therefore look at a broader class of patients with insomnia (and also a larger number of control participants, given the wide variation in circadian phase in the general population). In addition, we used sleep diaries to determine sleep timing information. It is possible that some of the insomnia patients misestimated their sleep onset timing, Similarly, given that we did not have complete circadian phase data sets in our paired analysis, we were likely underpowered to detect a difference between patients and controls.
In summary, we found that circadian phase is on average later in patients with insomnia compared to controls, and that between 10% and 22% of patients have a circadian phase abnormality in their sleep timing. This circadian misalignment may cause them to attempt sleep too early in their circadian cycle, thus lengthening their sleep latency and potentially compounding their insomnia symptoms. This subset of individuals is currently not identified in clinical practice and may require additional (circadian) treatment strategies than other patients with insomnia. We therefore suggest adoption of simple outpatient methods to measure circadian phase and identify these patients in order to better characterize phase-angle abnormalities, facilitate a differential diagnoses, and to inform the development of appropriately-timed circadian-based treatments.
